Symbols

AIDX

20/20 Biolabs·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AIDX

20/20 Biolabs, Inc.

Industry

Healthcare Providers and Services

Established Date

08/07/2000

Listing Date

02/19/2026

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

2020biolabs.com

Security Type

Common stock

Office address

15810 Gaither Road Suite 235 Gaithersburg MD 20877

Business

Introduction

20/20 Biolabs, Inc., was incorporated in Delaware on August 7, 2000. The company develops and commercializes artificial intelligence-driven, lab-based blood tests focused on early detection and prevention of cancer and chronic diseases. The company offers two main families of laboratory tests under the OneTest brand: OneTest for Cancer, a multi-cancer early detection blood test, and OneTest for Longevity, which is expected to launch in the first half of 2026. Both tests are performed at the company's CAP-certified and CLIA-licensed laboratory in Gaithersburg, Maryland, which also houses a clinical laboratory innovation accelerator designed for diagnostic start-ups.

Company Financials

EPS

Revenue & Expenses

AIDX has released its 2024 Q4 earnings report, with revenue of 536.08K, reflecting a YoY change of NaN%, and net profit of -1.25M, showing a YoY change of NaN%. The Sankey diagram below clearly presents AIDX's revenue sources and cost distribution.